- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
EFFICACY AND SAFETY OF PAZOPANIB FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA: A SINGLE-INSTITUTION STUDY
-
- Harada Kenichi
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Shiraishi Yusuke
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Suzuki Kohtaro
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Okamura Yasuyoshi
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Bando Yukari
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Hara Takuto
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Terakawa Tomoaki
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Furukawa Junya
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Ishimura Takeshi
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Shigemura Katsumi
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Hinata Nobuyuki
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Nakano Yuzo
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
-
- Fujisawa Masato
- Department of Urology, Kobe Uuiversity Graduate School of Medicine
Bibliographic Information
- Other Title
-
- 進行性腎癌に対する一次治療におけるパゾパニブの成績
Search this article
Description
<p>To investigate the efficacy and safety of first-line Pazopanib advanced or metastatic renal cell carcinoma (RCC): a single-institution study.</p><p> (Patients and methods) We gathered 23 RCC patients treated between April 2014 and February 2018 in our institution and examined the treatments outcome and adverse events (AEs).</p><p> (Results) Their risk criteria were categorized as follows: Favorable (n=2), Intermediate (n=12) and Poor (n=9) by International mRCC Database Consortion (IMDC). Median progression free survival (PFS) was 8.6 months and median overall survival (OS) was unreached. Best response (BR) of Pazopanib was partial response (PR): n=10, 50.0%, stable disease (SD): n=8, 40.0% and progression disease (PD): n=2, 10.0% (Three patients had no evaluable data,). AEs of Grade3 had liver dysfunction (n=3), thrombocytopenia (n=2), hand-foot syndrome (n=1), vomiting (n=1) and bowel bleeding (n=1).</p><p> (Conclusion) The fist-line pazopanib demonstrated good clinical benefit with well-tolerance.</p>
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 109 (4), 216-219, 2018-10-20
THE JAPANESE UROLOGICAL ASSOCIATION
